Niagen Bioscience (NASDAQ:NAGE) Raised to Strong-Buy at Wall Street Zen

Key Points

• Niagen Bioscience has been upgraded to a "strong-buy" rating by Wall Street Zen, reflecting increased confidence in the company's stock.
• Several analysts have raised their target prices for Niagen, with HC Wainwright setting it at $12.00 and Roth Capital at $23.00, indicating a strong bullish sentiment among investors.
• In its most recent earnings report, Niagen exceeded expectations with a revenue of $31.12 million and an EPS of $0.04, highlighting the company's strong financial performance.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) was upgraded by Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued to clients and investors on Saturday.

Other equities research analysts also recently issued research reports about the company. Roth Capital reaffirmed a "buy" rating and issued a $23.00 target price (up previously from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th. HC Wainwright upped their target price on Niagen Bioscience from $11.00 to $12.00 and gave the stock a "buy" rating in a research report on Monday, August 11th. Finally, Canaccord Genuity Group upped their target price on Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $13.42.

Niagen Bioscience Price Performance

NAGE stock remained flat at $9.63 during trading on Friday. The company's stock had a trading volume of 536,548 shares, compared to its average volume of 1,259,231. The firm's 50-day simple moving average is $11.34 and its 200 day simple moving average is $8.49. Niagen Bioscience has a 1 year low of $3.10 and a 1 year high of $14.69. The firm has a market cap of $767.99 million, a price-to-earnings ratio of 45.86 and a beta of 2.12.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.The firm had revenue of $31.12 million during the quarter, compared to the consensus estimate of $28.55 million.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. State of Wyoming acquired a new position in shares of Niagen Bioscience in the fourth quarter worth about $39,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Niagen Bioscience in the fourth quarter worth about $53,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Niagen Bioscience in the fourth quarter worth about $67,000. ProShare Advisors LLC acquired a new stake in Niagen Bioscience during the fourth quarter valued at approximately $74,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in Niagen Bioscience during the fourth quarter valued at approximately $94,000. Institutional investors and hedge funds own 15.41% of the company's stock.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.